Skip to main content
OpenTrials
Completed

NCT Number: NCT03366077

Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection in Adult Women

Urinary tract infections (UTIs) are the most common bacterial infections in women, with about 50% of women experiencing at least one UTI in their lifetime.

The main pharmacological treatments of cystitis usually involve the use of antibiotics, in particular quinolones (such as ciprofloxacin and levofloxacin), fosfomycin, second-generation and third-generation cephalosporins, and b-lactam antibiotics associated with b-lactamase inhibitors.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Clinical Trial Consultants AB

Uppsala, 752 37, Sweden

About this study

This is a double-blinded, randomized, placebo-controlled, parallel-group study evaluating the effect of the probiotic on recurrent urinary tract infection (UTI) in adult women recently treated for UTI.

Primary objective The primary objective is to evaluate the effect of oral supplementation with probiotic on the frequency of UTI during six months from start of intervention in adult women with recurrent UTI.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to give informed consent for participation in the study.
  • Woman aged 18-50 years old at screening.
  • BMI ≥18 at screening.
  • Currently on antibiotic treatment for UTI, at the time of screening. Antibiotic treatment must stop within three days prior to first IP dose.
  • Recurrent UTI defined as at least two UTIs during the last six months or at least three UTIs during the last 12 months, according to information given by the subject.
  • Able and willing to comply with the restrictions defined for the the study period (see Section 10.6).
  • Access to Bank ID and ability to use the e-health platform (i.e. Internet access).
  • Ability to understand and comply with the requirements of the study, as judged by the Investigator.

Exclusion criteria

  • Postmenopausal (defined as 12 months of amenorrhoea).
  • Pregnant or breastfeeding.
  • Planning to become pregnant during the study.
  • Irregular menstruations combined with perimenopausal symptoms.
  • Known hypersensitivity or allergy to any of the components of the test product, or to the comparator (placebo).
  • Use of spermicide contraceptives including spermicidal condom within three days prior to first IP dose.
  • History of complicated cystitis, urgency incontinence, recent pyelonephritis, urological and/or gynaecologist abnormalities, immunocompromised, as judged by the Investigator.
  • Unstable bowel disorder such as diarrhoea, Crohn's disease, ulcerative colitis.

-

Treatment and study plan

Probiotic

Dietary Supplement

Probiotic

Primary outcomes

  1. To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI.

    Time frame: 6 months

    Mean number (Standard Deviation) of confirmed UTIs in adult women with recurrent UTI, during six months from start of intervention, as compared to placebo.

Secondary outcomes

  1. To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the -Frequency of Confirmed UTI -Time to First Relapse of UTI. -Relapse Rate -Assess the Tolerability

    Time frame: 6 month

    Mean number of confirmed UTIs during the three months intervention period, as compared to placebo.

    Mean number of confirmed UTIs during the three months follow-up period, as compared to placebo.

    Mean time from start of intervention to first relapse of UTI, as compared to placebo.

    Proportion of subjects (%) who experienced at least one confirmed UTI during three months from start of intervention, as compared to placebo.

    Proportion of subjects (%) who experienced at least one confirmed UTI during six months from start of intervention, as compared to placebo.

    Occurrence and frequency of Adverse Events (AEs).

Sponsors and collaborators

Lead sponsor

BioGaia AB

Industry

Registry information

Official study title

A Double-blinded, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection (UTI) in Adult Women Recently Treated for UTI.

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Dec 8, 2017
Registry last updated
Sep 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.